Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))

Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope S.; Castrellon, Aurelio; Joy, Anil Abraham; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana Theall, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; Loibl, Sibylle; Finn, Richard S.

doi:10.1016/j.breast.2019.11.010

서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

S-Space

Publications

Detailed Information

Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033)) : Efficacy + safety of palbociclib (P) in patients (pts) <= 50 y with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (vol 41s1, pg s11, 2018)

DC Field	Value	Language
dc.contributor.author	Cristofanilli, Massimo	-
dc.contributor.author	Harbeck, Nadia	-
dc.contributor.author	Rugo, Hope S.	-
dc.contributor.author	Castrellon, Aurelio	-
dc.contributor.author	Joy, Anil Abraham	-
dc.contributor.author	Verma, Sunil	-
dc.contributor.author	Im, Seock-Ah	-
dc.contributor.author	Iyer, Shrividya	-
dc.contributor.author	Puyana Theall, Kathy	-
dc.contributor.author	Gauthier, Eric	-
dc.contributor.author	Huang, Xin	-
dc.contributor.author	Bartlett, Cynthia Huang	-
dc.contributor.author	Loibl, Sibylle	-
dc.contributor.author	Finn, Richard S.	-
dc.date.accessioned	2023-03-24T01:09:30Z	-
dc.date.available	2023-03-24T01:09:30Z	-
dc.date.created	2022-04-15	-
dc.date.created	2022-04-15	-
dc.date.issued	2020-02	-
dc.identifier.citation	Breast, Vol.49, pp.131-131	-
dc.identifier.issn	0960-9776	-
dc.identifier.uri	https://hdl.handle.net/10371/189753	-
dc.description.abstract	© 2019 Elsevier LtdTwo of the authors names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.	-
dc.language	영어	-
dc.publisher	Churchill Livingstone	-
dc.title	Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))	-
dc.title.alternative	Efficacy + safety of palbociclib (P) in patients (pts) <= 50 y with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (vol 41s1, pg s11, 2018)	-
dc.type	Article	-
dc.identifier.doi	10.1016/j.breast.2019.11.010	-
dc.citation.journaltitle	Breast	-
dc.identifier.wosid	000512925000019	-
dc.identifier.scopusid	2-s2.0-85075628192	-
dc.citation.endpage	131	-
dc.citation.startpage	131	-
dc.citation.volume	49	-
dc.description.isOpenAccess	Y	-
dc.contributor.affiliatedAuthor	Im, Seock-Ah	-
dc.type.docType	Erratum	-
dc.description.journalClass	1	-